Clinical Trials in Pittsburgh

Showing 20441-20460 of 21,047 trials

Safety and Efficacy of NeuroFlo in 8-24 Hour Stroke Patients

NCT00436592

The purpose of this study is to assess the safety and feasibility of the NeuroFlo™ catheter in treating patients with ischemic stroke whose last time symptom-free was between 8-24 hours prior to treatment. The NeuroFlo device is intended to increase blood flow to the brain and potentially reduce the damage caused by stroke.

Cerebrovascular Accident

CoAxia26 participantsStarted Feb 2007

Los Angeles, California, United States • Boston, Massachusetts, United States • Rochester, New York, United States +7 more locations

COMPLETEDPhase 4< 1 mile

To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia

NCT00007774

Although currently marketed antipsychotic drugs are useful in the treatment of schizophrenia, efficacy and safety profiles need to be improved. Forty to eighty percent of patients either fail to respond or only partially respond to conventional antipsychotic agents. Secondary symptoms may be unimproved even in patients who respond to treatment. A variety of adverse events occur in patients receiving currently available agents. The severity of these events contributes to the poor compliance that is observed in this patient population. Olanzapine is a novel antipsychotic agent with a reduced incidence of extrapyramidal symptoms. Other side effects are minimal.

Schizoaffective DisorderSchizophrenia

US Department of Veterans Affairs600 participantsStarted Mar 1998

Tuscaloosa, Alabama, United States • Palo Alto, California, United States • West Haven, Connecticut, United States +15 more locations

Safety and Efficacy of NeuroFlo in 8-24 Hour Stroke Patients

To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia

Find Trials by Condition in Pittsburgh

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

Hypertension Screening and Treatment Program

Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients

Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome

Surgery Followed by Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer

Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia

Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)

Immediate Treatment vs Colposcopic Follow-up for Biopsy-Proven CIN 1

The Oscillation for ARDS Treated Early (OSCILLATE) Trial Pilot Study

Cardiac Arrest Recovery EEG Study

An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients

Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer

Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma

Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice

Chromocolonoscopy for the Detection of Flat Adenomas in Routine Colorectal Cancer Screening.

An Eight-Week Study Evaluating the Efficacy of Two Fixed Doses (250 mg Twice Daily and 100 mg Twice Daily) of SSR149415 in Patients With Major Depressive Disorder

Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes